The evolution of hematopoietic SCT in myelodysplastic syndrome (Q37404489)

20 August 2017

1 reference

title

The evolution of hematopoietic SCT in myelodysplastic syndrome (English)

1 reference

20 August 2017

T Kindwall-Keller

1

1 reference

20 August 2017

L M Isola

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

2 March 2009

1 reference

Bone Marrow Transplantation

20 August 2017

published in

1 reference

20 August 2017

volume

43

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

597-609

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2009.28

20 August 2017

exact match

0 references

cites work

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

Myelodysplastic syndromes: incidence and survival in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Successful allogeneic bone marrow transplantation in selected patients over 50 years of age--a single institution's experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the F

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.28

7 January 2021

Identifiers

DOI

10.1038/BMT.2009.28

1 reference

20 August 2017

1 reference